Navigation Links
Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Date:10/2/2007

co-director of the breast cancer program at the Indiana University

Cancer Center. He is also professor of medicine and pathology at

Indiana University School of Medicine. Dr. Sledge was awarded the Komen

Brinker Award of Scientific Distinction in 2006.

-- Sara Sukumar, Ph.D., professor of oncology and pathology and co-

director of the breast cancer research program at the Sidney Kimmel

Cancer Center at Johns Hopkins University School of Medicine in

Baltimore.

About Susan G. Komen for the Cure

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure and launched the global breast cancer movement. Today, Komen for the Cure is the world's largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure, we have invested nearly $1 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world. For more information about Susan G. Komen for the Cure, breast health or breast cancer, visit http://www.komen.org or call 1-800 I'M AWARE.


'/>"/>
SOURCE Susan G. Komen for the Cure
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Scientific markers of aging described
2. A Settlement Over Stem Cell Controversy Through Scientific Research
3. A Scientific Explanation For Out Of Body Experience
4. PUFA Good For Heart: Gets The Scientific Seal
5. Forensic Phonetics – Scientific Solution for Legal Problem
6. Old Indian Advice Has A Scientific Backing Now!
7. India To Highlight Its Scientific Achievements
8. Thumbs up in weight loss for vegetarian diets: scientific review
9. Scientific Research in a War Zone
10. Unscientific Depression Drugs aplenty in Health Stores
11. No Scientific Evidence to Support Drug Safety Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:Pitt study suggests craving hinders comprehension without your realizing it 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:Wellness Cruise Offers Crystal Guests 'Indian Ocean Insight' 2Health News:VitaminSpice Signs Agreement With Former CEO of Wal-Mart Stores Division for US Distribution 2
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist Competition 57518 1Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist Competition 57518 2Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 1Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 2Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 3Bolder BioTechnology Receives 241 2 Million NIH Grant to Continue Development of Long Acting EPO Analog for Chronic Kidney Disease 14125 4Alzheimers Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Propos 57510 1Alzheimers Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Propos 57510 2Alzheimers Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Propos 57510 3